Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-75276617 |
Synonyms | |
Therapy Description |
JNJ-75276617 inhibits the interaction between menin and MLL, leading to decreased expression of target genes, potentially resulting in inhibition of cell proliferation of tumor cells harboring gene rearrangements, duplications or amplifications in KMT2A or gene alterations in NPM1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-75276617 | JNJ 75276617|JNJ75276617 | MEN1-KMT2A Inhibitor 8 | JNJ-75276617 inhibits the interaction between menin and MLL, leading to decreased expression of target genes, potentially resulting in inhibition of cell proliferation of tumor cells harboring gene rearrangements, duplications or amplifications in KMT2A or gene alterations in NPM1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04811560 | Phase I | JNJ-75276617 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia | Recruiting | USA | GBR | FRA | ESP | AUS | 1 |